Collection / Tesamorelin 40mg
Tesamorelin 40mg
Tesamorelin is a GHRH analogue studied for growth-axis responses and visceral-fat endpoints. Reviewed trials in adults with HIV-associated abdominal fat accumulation provide a specific clinical research context.
Simulation only · No real order or payment.
GHRH analogue · growth-axis research
Also known as: TH9507
Human trialResearch & handling
Not for human or veterinary use. Storage, handling, identity and purity require verified batch documentation. No dosing or treatment advice is provided.
At a glance
GHRH analogue
Its identity centres on growth-hormone-releasing hormone signalling.
Visceral-fat research
Imaging endpoints quantify abdominal visceral fat in the studied population.
Hormone responses
GH/IGF-1 endpoints remain tied to controlled trial conditions.
Explore the study context and sources below. For laboratory research only.
Studies & context
Studied in adults with HIV-associated abdominal fat accumulation for imaging-measured visceral fat and hormone changes.
Human trialA 26-week randomized trial in 412 patients reported reduced visceral fat and increased IGF-I.
Study limitations
A specific fat compartment and patient population, not general weight loss or performance evidence.
Withdrawals due to adverse events were more frequent in the treatment group.
Study limitations
The trial medicine was not PEPTIVIA’s vial or pen formulation.
Published research is separate from PEPTIVIA identity, content, purity, sterility and batch documentation. No source-supplier report verifies PEPTIVIA material.